Table 1 Baseline clinical characteristics of patients
Variable | Patients with visceral obesity, n = 160 | Patients without visceral obesity, n = 72 | p |
|---|---|---|---|
Men | 58 (54;69) | 57 (50;67) | 0.92 |
Arterial hypertension, n (%) | 160 (100.0) | 60 (83.3) | 0.05 |
Current smoking | 65 (40.6) | 39 (54.2) | 0.46 |
Family history of IHD | 105 (65.6) | 24 (33.3) | 0.04 |
Family history of T2DM | 35 (21.9) | 8 (11.1) | 0.04 |
Features history | |||
Angina prior to myocardial infarction | 85 (53.1) | 48 (66.6) | 0.69 |
Previous myocardial infarction | 31 (19.3) | 13 (18.1) | 0.051 |
History of heart failure | 16 (10) | 8 (11.1) | 0.81 |
History of cerebrovascular accident/transient ischemic attack | 0 | 3 (4.2) | 0.98 |
Myocardial infarction | |||
Q-wave myocardial infarction | 128 (80) | 58 (80.5) | 0.61 |
Non-Q-wave myocardial infarction | 33 (20.3) | 15 (20.8) | 0.62 |
Localization of myocardial infarction | |||
- posterior | 105 (65.6) | 38 (54.2) | 0.61 |
- posterior with extension to the right | |||
ventricle | 18 (12.3) | 10 (13.9) | 0.72 |
- anterior | 30 (18.8) | 20 (27.8) | 0.59 |
- inferio- posterio-lateral | 8 (5) | 6 (8.3) | 0.79 |
Acute heart failure (Killip classification) | |||
I | 110 (68,8) | 44 (61.1) | 0.52 |
II | 31 (19.4) | 17 (23.6) | 0.64 |
III | 15 (9,4) | 10 (13.8) | 0.72 |
IV | 3 (1.9) | 0 | 0.95 |
- Rhythm disturbance | 38 (23.8) | 20 (27.8) | 0.78 |
Early post-infarction angina | 30 (18.8) | 16 (22.2) | 0.71 |
Recurrent myocardial infarction | 10 (6.3) | 3 (4.2) | 0.91 |
Creatine phosphokinase, U/L | 339.2 (203.1;699.4) | 245 (110.7;523.1) | 0.03 |
Max creatine phosphokinase-MB, U/L | 81 (33;179) | 66 (35;142) | 0.03 |
Troponin T, ng/ml | 1.01 (0.82;3.1) | 0.69 (0.17;1.2) | 0.01 |
Left ventricular ejection fraction, % | 50 (40;57) | 52 (42;53) | 0.60 |
Number of diseased coronary arteries | |||
Stenosis of a vessels | 28 (17.5) | 16 (22.2) | 0.72 |
Stenosis of 2 vessels | 15 (9.4) | 26 (36.1) | 0.03 |
Stenosis of 3 or more vessels | 122 (76.3) | 14 (43.1) | 0.03 |
Treatment strategy/group of drugs | |||
Stenting of the infarct-related artery | 160 (100) | 72 (100) | 0,81 |
Systemic thrombolytic therapy | 13 (8.1) | 10 (13.8) | 0.73 |
β-blockers | 140 (87.5) | 72 (100) | 0,82 |
Angiotensin-converting enzyme | 145 (90.6) | 68 (42.5) | 0.59 |
Calcium channel blocker | 120 (78.1) | 62 (38.8) | 0.97 |
Diuretics | 53 (33.1) | 26 (36.1) | 0.81 |
Nitrates | 26 (15.6) | 15 (20.8) | 0.80 |
Aspirin | 160 (100) | 71 (98.6) | 0.91 |
Heparin | 160 (100) | 72 (100) | 0.98 |
Clopidogrel | 148 (92.5) | 62 (95.8) | 0.81 |
Statins | 160 (100.0) | 72 (100.0) | 0.93 |